These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20015594)

  • 1. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
    Saad F; Lipton A
    Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
    Mayer EL; Krop IE
    Clin Cancer Res; 2010 Jul; 16(14):3526-32. PubMed ID: 20634194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
    Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
    Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Src as a therapeutic target in men with prostate cancer and bone metastases.
    Saad F
    BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
    Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy.
    Rucci N; Recchia I; Angelucci A; Alamanou M; Del Fattore A; Fortunati D; Susa M; Fabbro D; Bologna M; Teti A
    J Pharmacol Exp Ther; 2006 Jul; 318(1):161-72. PubMed ID: 16627750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A
    Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of aqueous extracts of Taraxacum officinale on growth and invasion of breast and prostate cancer cells.
    Sigstedt SC; Hooten CJ; Callewaert MC; Jenkins AR; Romero AE; Pullin MJ; Kornienko A; Lowrey TK; Slambrouck SV; Steelant WF
    Int J Oncol; 2008 May; 32(5):1085-90. PubMed ID: 18425335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
    Dorai T; Dutcher JP; Dempster DW; Wiernik PH
    Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
    Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
    Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
    Pohorelic B; Singh R; Parkin S; Koro K; Yang AD; Egan C; Magliocco A
    Breast Cancer Res Treat; 2012 May; 133(1):201-14. PubMed ID: 21894461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of tumor metastasis to the bone: challenges and opportunities.
    Reddi AH; Roodman D; Freeman C; Mohla S
    J Bone Miner Res; 2003 Feb; 18(2):190-4. PubMed ID: 12568395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.